TickerTalks
Browse all tickers →
TickerTalks›$VKTX
VKVKTX

Viking Therapeutics, Inc.

$VKTX·$3.7B·Biotechnology·Healthcare
$32.78+1.9%YTD-7.3%1Y+19.2%
Mentions · last 7 days
2026-08-22: 12 posts2026-08-23: 18 posts215-5%
Price updated 7h ago·X counts updated 8d ago
VKVKTX
$VKTXViking Therapeutics, Inc.
$32.78+1.93%215 posts-5%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $VKTX, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventEvent coming upAI verdict · as of 2026-08-30

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

The GLP-1 challenger biotech with a mid-September VK2735 readout, $502M in cash, and a real weight-loss-to-tolerability story.

Viking Therapeutics is a clinical-stage biotech running one of the most credible non-Lilly, non-Novo GLP-1 programs — VK2735, an injectable and oral obesity drug candidate. The whole equity is a bet on the September VK2735 readout, and the position is set.

How the setup reads:

  • The next catalyst is imminent: mid-September VK2735 data readouts approaching — for a clinical-stage biotech with zero revenue and a $3.7B market cap, this is the event; a clean readout rerates, a soft one is a 40-50% single-day drop.
  • Phase-3 Vanquish signal is encouraging: 10-15% vomit rate at >48 weeks with 0% discontinuation from vomit and many patients losing 20%+ body weight — a Zepbound-comparable efficacy with better tolerability, the differentiation you want.
  • Cash runway isn't the constraint: $502M cash at Q1, plus a fresh S-3ASR shelf July 30 for optional secondary — the shelf overhang is real (dilution risk post-readout) but runway is not immediately threatened.
  • Pre-revenue means the equity is binary: quarterly EPS -$1.37, cash burn accelerating into Phase-3 — this is a data-readout equity, not value.
  • Position at 46% of the 52-week range and 9% below the 50-day says options have taken some risk out — traders are adding October calls, the pattern of a de-risked binary entering the window.

The mid-September VK2735 readout decides it: a clean efficacy print with tolerability differentiation triggers a 40%+ rerate toward $45+; a mixed print sets up a 40-50% drop back to $18-20.

Agrees with X sentimentAgree — the bull anchors (mid-September readout timing, Vanquish 10-15% vomit rate with 0% discontinuation, patients at 20%+ body weight loss, CEO conference confidence, October call accumulation) map to real signals; the honest add is the July 30 S-3ASR shelf means any celebration is likely met with a secondary announcement.

What to watch: Mid-September VK2735 readout — a clean efficacy print with tolerability differentiation intact triggers a 40%+ rerate toward $45+; a mixed print sets up a 40-50% single-day drop back toward $18-20 support.

On the calendar: 2026-10-28 — Q3 earnings (VK2735 data mid-September)

float missing

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment30 posts analyzed · as of 2026-08-30

Anticipation is high heading into a Phase 2 maintenance readout for VK2735, with posters citing a slower Phase 3 titration and calling 18-19% weight loss at 21 weeks the sweet spot for a rerating. Adds around $32-34 are shared as risk/reward is 'ridiculous,' oral pill optionality remains, and traders eye a Moderna-style short cover. Some fret about GI tolerability but few see the data disappointing.

Read the AI verdict + X sentiment for $VKTX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops GLP-1/GIP receptor agonists for obesity and NASH in both subcutaneous and oral formulations.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $VKTX.

Biotechnology · Healthcare

GLP-1 oral formulation competition — emerging clinical data from pipeline challengers — is the central bifurcation: platform holders (LLY, NVO) defend on efficacy breadth while precision oncology names decouple entirely. FDA catalyst cadence over the next 60 days sets the near-term tone.

What this means for $VKTX

Partial — fee-based midstream revenue has limited direct commodity price exposure but volume ties to upstream production activity.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+48.9%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-7.0How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-100%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-10.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-71.3%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 29, 2026$-1.10$-1.23+10.6%
Q1 2026Apr 29, 2026$-1.37$-1.01-35.6%
Q4 2025Feb 11, 2026$-1.38$-0.89-55.1%
Q3 2025Oct 22, 2025$-0.81$-0.70-15.7%
Next earningsWed, Oct 28·consensus EPS $-1.07

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-1.37$-114.0M
Q4 FY25$0———$-1.38$-85.3M
Q3 FY25$0———$-0.81$-94.0M
Q2 FY25$0———$-0.58$-47.1M

Forward consensus

5-year forecast · up to 16 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$7.2M$7.2M – $7.2M-$4.75-$5.78 – -$3.859
FY27$7.3M$7.3M – $7.3M-$4.77-$6.82 – -$2.3610
FY28$161.5M$161.5M – $161.5M-$3.91-$6.76 – -$0.2616
FY29$474.5M$474.5M – $474.5M-$1.73-$1.73 – -$1.7315
FY30$1.2B$1.2B – $1.2B$2.16$2.16 – $2.1615

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.9×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.49%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-7.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-2.5%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 113.4M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.5% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.695-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJul 29Brian LianCEO148.5K sh$4.9MSellJul 29Greg ZanteCFO21.2K sh$710KSellJul 29Marianna ManciniCOO18.2K sh$610KBuyMar 10Aubuchon Neil WilliamChief Commercial Officer4.5K sh$150K
+ 5 other (5 awards) in window

See when $VKTX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsAug 73
AI summary

A reporting person filed an initial Form 3 at Viking Therapeutics (VKTX), disclosing no securities are beneficially owned — no common stock, options, or derivative securities. This is a routine initial Section 16 reporting obligation for a new insider or 10%-plus holder.

S-3ASRAuto-shelf registrationJul 30S-3ASR
AI summary

Viking Therapeutics, Inc. (VKTX) filed an automatic shelf registration (S-3ASR) as a large accelerated filer, registering securities for offerings from time to time, including a sales agreement prospectus for an ATM facility of up to $500 million of common stock through Stifel, Piper Sandler, Cantor Fitzgerald, and Oppenheimer. The shelf registration enables both primary issuances and selling shareholder resales. This is a standard capital markets flexibility tool; the $500M ATM represents potential dilution for Viking shareholders but is not an immediate offering.

3New insider — initial holdingsJun 33
AI summary

A new insider filed a Form 3 with the SEC, disclosing initial beneficial ownership of VKTX securities. This filing is required under Section 16(a) of the Securities Exchange Act within 10 days of becoming a reporting person (officer, director, or 10%+ holder). The filing reports 4 shares of common stock. Form 3 filings establish a baseline ownership record for subsequent Form 4 (changes) and Form 5 (annual) filings, providing transparency into insider positions at VKTX.

8-KShareholder voteMay 268-K — Item 5.07: Shareholder vote
AI summary

Viking Therapeutics held its 2026 Annual Meeting on May 19, 2026 with 80.1M of 115.9M shares (69.1%) represented. Elected Class II directors for terms through 2029: J. Matthew Singleton (28.6M for, 14.6M withheld) and S. Kathryn Rouan, Ph.D. (22.0M for, 21.3M withheld—notably contested). Ratified CBIZ CPAs P.C. as auditor (78.4M for, 1.2M against). Rouan's high withhold vote (~49% of non-broker votes) is the notable outcome and may reflect institutional governance concerns.

+ 9 other (2 10-Qs · 2 earnings 8-Ks · 2 13Gs · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Consensus Rating of “Moderate Buy” by Brokeragesdefenseworld.net·1d agoViking Therapeutics Stock Is Down 66% From Its Peak. Here's What Comes Next.fool.com·2d agoWhy Is Viking Therapeutics (VKTX) Up 2.3% Since Last Earnings Report?zacks.com·4d agoViking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough?fool.com·5d agoLLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?zacks.com·15d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALT$AURA$IOVA$NWBO$SLS$AMLX$ABCL
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport